WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130235
CAS#: 1579514-06-9
Description: BI685509 is a soluble guanylate cyclase (sGC) activator taken orally, with potential to treat diabetic and kidney diseases. In both rat and human platelets, BI685509 was found to restore/enhance cGMP, but had no effect on the functionality of nitric oxide pathways. BI685509 is currently undergoing phase 2 trials for the treatment of diabetic nephropathy, with the aim of improving kidney function.
Hodoodo Cat#: H130235
Name: BI685509
CAS#: 1579514-06-9
Chemical Formula: C34H38N4O5
Exact Mass: 582.28
Molecular Weight: 582.700
Elemental Analysis: C, 70.08; H, 6.57; N, 9.62; O, 13.73
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BI685509; BI 685509; BI-685509
IUPAC/Chemical Name: 5-ethoxy-1-(6-(3-methyl-2-((5-methyl-2-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methoxy)phenyl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid
InChi Key: KWNFFNFBUMFTHK-UHFFFAOYSA-N
InChi Code: InChI=1S/C34H38N4O5/c1-4-42-33-29(34(39)40)19-35-38(33)31-10-6-9-30(36-31)28-8-5-7-22(2)32(28)43-21-25-12-11-24-20-37(16-13-27(24)23(25)3)26-14-17-41-18-15-26/h5-12,19,26H,4,13-18,20-21H2,1-3H3,(H,39,40)
SMILES Code: O=C(C1=C(OCC)N(C2=NC(C3=CC=CC(C)=C3OCC4=C(C)C5=C(CN(C6CCOCC6)CC5)C=C4)=CC=C2)N=C1)O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 582.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1. Reinhart GA, Harrison PC, Lincoln K, Chen H, Sun P, Hill J, Qian HS, McHugh MC, Clifford H, Ng KJ, Wang H, Fowler D, Gueneva-Boucheva K, Brenneman JB, Bosanac T, Wong D, Fryer RM, Sarko C, Boustany-Kari CM, Pullen SS. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease. J Pharmacol Exp Ther. 2023 Mar;384(3):382-392. doi: 10.1124/jpet.122.001423. Epub 2022 Dec 6. PMID: 36507845.
2. https://www.pharmaceutical-technology.com/data-insights/bi-685509-boehringer-ingelheim-international-diabetic-nephropathy-likelihood-of-approval/
3. https://clinicaltrials.gov/ct2/show/NCT04750577
4. https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3609386
